查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447030

到 2030 年二肽肽酶 4 抑制剂市场预测 - 按药物类型、应用和地理位置进行的全球分析

Dipeptide Peptidase 4 Inhibitor Market Forecasts to 2030 - Global Analysis By Drug Type, Application and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球二肽肽酶 4 抑制剂市场规模为 113 亿美元，预计到 2030 年将达到 156.9 亿美元，预测期内复合CAGR为 4.8%。一类称为二肽基肽酶 4 (DPP-4) 抑制剂的药物用于治疗第 2 型糖尿病。 DPP-4 酵素负责分解肠促胰岛素激素，而肠促胰岛素激素对于控制血糖水平至关重要。这些药物透过阻断DPP-4 来发挥作用，DPP-4 会增加肠促胰岛素的作用，特别是胰高血糖素样胜肽-1 (GLP-1)，它会增加胰岛素分泌并降低胰高血糖素的产生。结果，血糖水平降低，葡萄糖调节增强。

根据美国糖尿病协会的说法，二肽基肽酶 4 (DPP-4) 抑制剂是治疗第 2 型糖尿病的一类有价值的药物。这些抑制剂透过靶向 DPP-4 酶，增强肠促胰岛素激素的有效性，有助于改善血糖控制。

市场动态：

司机：

糖尿病发生率上升

二肽基肽酶 4 (DPP-4) 抑制剂的市场受到全球糖尿病盛行率持续上升的显着推动。到 2030 年，全球估计将有 5.37 亿人患有糖尿病，对高效糖尿病药物的需求日益增长。此外，DPP-4抑制剂透过为第2型糖尿病患者提供可行的治疗选择来满足这一需求，从而促进市场的整体成长。

克制：

潜在的安全问题

儘管二肽基肽酶 4 (DPP-4) 抑制剂总体上具有良好的安全性，但仍引发了一些安全性问题。由于有报告指出胰臟炎和关节疼痛等不常见但危险的副作用，患者和医疗保健专业人员可能不愿意服用某些药物。此外，必须承认和理解这些可能的危害，以确保 DPP-4 抑制剂在业界的持续可信度和批准。

机会：

扩展治疗指南和适应症

二肽基肽酶 4 (DPP-4) 抑制剂的潜在机会包括将这些药物纳入更新的治疗指南以及可能扩大其适应症。此外，正在进行的研究和临床试验可能会扩大适应症以及市场成长和采用的新途径，以检验 DPP-4 抑制剂在特定患者群体中或与其他疗法相结合的优势。

威胁：

价格压力与普遍侵蚀

当品牌药专利到期时，DPP-4抑制剂市场面临仿製药侵蚀威胁的挑战。当通常以较低成本提供的通用替代品可用时，价格压力可能会增加。此外，生产品牌版本的製药公司可能会因这种现象而导致获利能力下降，这可能会影响他们在研发和行销资源上的投资。

Covid-19 影响：

二肽基肽酶 4 (DPP-4) 抑制剂市场在许多方面受到了 COVID-19 大流行的影响。处方模式和病患依从性受到病患优先事项变化、医疗保健系统中断和财务困难的影响。远距医疗的采用急剧增加，影响了病患互动和药品销售的传统动态。此外，儘管抗糖尿病药物的需求仍然强劲，但市场仍存在波动。这凸显了製药公司需要保持创新和灵活性，以应对全球健康危机的持续影响。

西格列汀业务预计在预测期内成为最大的业务

预计西格列汀细分市场将拥有最大的市场份额。西他列汀以多个品牌出售，是治疗第 2 型糖尿病的常用处方药。它透过抑制 DPP-4 酶发挥作用，从而显着降低血糖水平。其良好的安全性、口服给药的简便性以及已证实的改善血糖控制的能力是其受欢迎的原因。此外，西格列汀凭藉其广泛的用途和丰富的临床经验，在DPP-4抑制剂市场上占有重要地位。

预计诊所业务在预测期内复合CAGR最高

市场CAGR最高的是诊所领域。这种模式显示患者偏好和医疗保健提供方式发生了变化。诊所因提供定期检查、预防性护理和专门治疗等各种医疗服务而变得越来越受欢迎。他们的特点是更容易获得和方便的医疗服务。对门诊护理的需求不断增长以及对个人化和社区医疗保健的日益重视推动了诊所的快速扩张。此外，由于效率高、等待时间短以及为患者提供个人化护理，诊所的成长速度更快。

占比最大的地区：

北美拥有二肽肽酶 4 (DPP-4) 抑制剂最大的市场份额。一类称为 DPP-4 抑制剂的药物用于治疗第 2 型糖尿病。由于多种原因，北美在 DPP-4 抑制剂市场中占有相当大的份额。首先，该地区 2 型糖尿病的高发生率加剧了对有效治疗方案的需求。根据美国疾病管制与预防中心 (CDC) 的数据，大多数美国人（约 3,400 万人）患有第 2 型糖尿病。此外，北美还拥有完善的医疗保健基础设施，其中包括製药公司、尖端的医学研究设施和监管框架。

复合CAGR最高的地区：

预计二肽肽酶 4 (DPP-4) 抑制剂市场将以亚太地区最高的CAGR成长。一类称为 DPP-4 抑制剂的药物用于治疗第 2 型糖尿病。亚太地区包括中国、印度、日本、澳洲等国。由于多种因素，亚太地区 DPP-4 抑制剂市场正在快速成长。该地区有很多人有患 2 型糖尿病的风险，或者已经被诊断出患有这种疾病，而且人口正在迅速增长。此外，这种人口趋势也为 DPP-4 抑制剂等糖尿病药物创造了相当大的市场。

主要进展：

2024 年 2 月，诺华宣布已达成协议，将自愿公开收购要约收购 MorphoSys AG。MorphoSys AG 是一家总部位于德国、开发肿瘤学创新药物的全球生物製药公司。根据一份新闻声明，此次收购须满足惯例成交条件，包括收购要约中所投标流通股的 65% 的最低接受门槛以及监管部门的批准。

2024 年 2 月，美国新泽西州罗韦市 Merck & Co., Inc. 的子公司默克动物保健公司（在美国和加拿大境外称为默沙东动物保健公司）宣布已签署收购水产品业务的最终协议以13 亿美元现金收购Elanco Animal Health Incorporated，其中包括针对水生物种的药物和疫苗、营养品和补充剂的创新组合；位于加拿大和越南的两个相关水产生产设施；以及智利的一个研究机构。

2023 年 11 月，勃林格殷格翰和 IBM 宣布达成协议，勃林格殷格翰将能够利用 IBM 的基础模型技术来发现新型候选抗体，以开发有效的疗法。勃林格殷格翰将使用 IBM 开发的预训练人工智慧模型，该模型将根据勃林格殷格翰的其他专有资料进行进一步微调。

我们的报告提供了什么：

  • 区域和国家层面的市场份额评估
  • 对新进入者的策略建议
  • 涵盖2021年、2022年、2023年、2026年及2030年的市场资料
  • 市场趋势（驱动因素、限制因素、机会、威胁、挑战、投资机会和建议）
  • 根据市场预测提出关键业务部门的策略建议
  • 竞争性景观美化绘製主要共同趋势
  • 公司概况，包括详细的策略、财务状况和最新发展
  • 反映最新技术进步的供应链趋势

免费客製化产品：

本报告的所有客户都将有权获得以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 个）
    • 关键参与者的 SWOT 分析（最多 3 个）
  • 区域细分
    • 根据客户的兴趣对任何主要国家的市场估计、预测和CAGR（註：取决于可行性检查）
  • 竞争基准化分析
    • 根据产品组合、地理分布和策略联盟对主要参与者基准化分析

目录

第 1 章：执行摘要

第 2 章：前言

  • 抽象的
  • 股东
  • 研究范围
  • 研究方法论
    • 资料探勘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究来源
    • 假设

第 3 章：市场趋势分析

  • 介绍
  • 司机
  • 限制
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • Covid-19 的影响

第 4 章：波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争竞争

第 5 章：全球二肽肽酶 4 抑制剂市场：按药物类型

  • 介绍
  • 西格列汀
  • 维格列汀
  • 沙格列汀
  • 利格列汀
  • 吉格列汀
  • 阿格列汀
  • 特力利汀
  • 其他药物类型

第 6 章：全球二肽肽酶 4 抑制剂市场：依应用分类

  • 介绍
  • 医院
  • 诊所
  • 其他应用

第 7 章：全球二肽肽酶 4 抑制剂市场：依地理位置

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 卡达
    • 南非
    • 中东和非洲其他地区

第 8 章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 扩充
  • 其他关键策略

第 9 章：公司概况

  • Merck
  • Boehringer Ingelheim
  • Novartis
  • AstraZeneca
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals
Product Code: SMRC25291

According to Stratistics MRC, the Global Dipeptide Peptidase 4 Inhibitor Market is accounted for $11.3 billion in 2023 and is expected to reach $15.69 billion by 2030 growing at a CAGR of 4.8% during the forecast period. A class of drugs called dipeptidyl peptidase 4 (DPP-4) inhibitors is used to treat type 2 diabetes. The enzyme DPP-4 is responsible for the breakdown of incretin hormones, which are essential for controlling blood sugar levels. These drugs work by blocking DPP-4, which increases the effect of incretins, specifically glucagon-like peptide-1 (GLP-1), which raises insulin secretion and lowers glucagon production. As a result, blood sugar levels are lowered, and glucose regulation is enhanced.

According to the American Diabetes Association, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors represent a valuable class of medications for the management of type 2 diabetes. These inhibitors, by targeting the DPP-4 enzyme, enhance the effectiveness of incretin hormones, contributing to improved blood sugar control.

Market Dynamics:

Driver:

Rising incidence of diabetes

The market for dipeptidyl peptidase 4 (DPP-4) inhibitors is significantly driven by the ongoing worldwide rise in the prevalence of diabetes. By 2030, there will be 537 million people worldwide estimated to have diabetes, creating a growing need for efficient diabetes medications. Furthermore, DPP-4 inhibitors meet this need by providing a workable treatment option for individuals with type 2 diabetes, thereby contributing to the overall growth of the market.

Restraint:

Potential safety issues

Dipeptidyl Peptidase 4 (DPP-4) inhibitors have raised some safety concerns despite having a generally good safety profile. Patients and healthcare professionals may be reluctant to take certain medications due to reports of uncommon but dangerous side effects, such as pancreatitis and joint pain. Moreover, it is imperative to acknowledge and comprehend these possible hazards in order to guarantee the sustained credibility and approval of DPP-4 inhibitors within the industry.

Opportunity:

Extending treatment guidelines and indications

Potential opportunities for Dipeptidyl Peptidase 4 (DPP-4) inhibitors include the inclusion of these drugs in updated treatment guidelines and the possible expansion of their indications. Additionally, expansion of indications and new paths for market growth and adoption may result from ongoing research and clinical trials examining the advantages of DPP-4 inhibitors in particular patient populations or in conjunction with other therapies.

Threat:

Price pressures and generic erosion

When the patents for branded drugs expire, the DPP-4 inhibitor market faces challenges from the threat of generic erosion. Price pressure may increase when generic alternatives, which are usually provided at a lower cost, are available. Furthermore, pharmaceutical companies that produce the branded versions may see a decrease in profitability as a result of this phenomenon, which could have an effect on their investment in R&D and marketing resources.

Covid-19 Impact:

The Dipeptidyl Peptidase 4 (DPP-4) inhibitor market has been impacted by the COVID-19 pandemic in many ways. Prescription patterns and patient adherence have been impacted by changes in patient priorities, disruptions in healthcare systems, and financial difficulties. The adoption of telehealth has increased dramatically, impacting the conventional dynamics of patient interactions and pharmaceutical sales. Additionally, the market has fluctuated even though the demand for anti-diabetic drugs has remained strong. This highlights the need for pharmaceutical companies to remain innovative and flexible in order to deal with the ongoing effects of the global health crisis.

The Sitagliptin segment is expected to be the largest during the forecast period

It is projected that the sitagliptin segment will have the largest market share. Sitagliptin, sold under several brand names, is a commonly prescribed drug for the treatment of type 2 diabetes. It works by inhibiting the DPP-4 enzyme, which significantly lowers blood sugar levels. Its favorable safety profile, ease of oral administration, and proven ability to improve glycemic control are the reasons for its popularity. Moreover, sitagliptin has a strong hold in the DPP-4 inhibitor market thanks to its broad usage and wealth of clinical experience.

The Clinics segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR has been seen in the clinic segment. This pattern points to a change in patient preferences and the ways that healthcare is delivered. Clinics are becoming more and more popular for offering a variety of medical services, such as regular check-ups, preventive care, and specialized treatments. They are distinguished by their more easily accessible and convenient healthcare services. The rapid expansion of clinics has been driven by the growing need for outpatient care as well as the growing emphasis on individualized and community-based healthcare. Additionally, clinics are growing more rapidly because of the efficiency, shorter wait times, and individualized care they provide to their patients.

Region with largest share:

North America holds the largest market share for dipeptide peptidase 4 (DPP-4) inhibitors. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. For a number of reasons, North America commands a sizable portion of the DPP-4 inhibitor market. First off, the need for efficient treatment options is fueled by the high rate of type 2 diabetes in the area. The majority of Americans with diabetes, approximately 34 million, have type-2 diabetes, according to the Centers for Disease Control and Prevention (CDC). Furthermore, North America also boasts a well-established healthcare infrastructure, which includes pharmaceutical companies, cutting-edge medical research facilities, and regulatory frameworks.

Region with highest CAGR:

The dipeptide peptidase 4 (DPP-4) inhibitor market is anticipated to grow at the highest CAGR in the Asia-Pacific region. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. The nations of China, India, Japan, Australia, and other countries are included in the Asia-Pacific region. The Asia-Pacific DPP-4 inhibitor market is growing at a rapid rate due to a number of factors. There are many people in the area who are either at risk of developing type-2 diabetes or who have already been diagnosed with the disease, and the population is growing quickly. Moreover, a sizeable market is created for diabetes drugs, such as DPP-4 inhibitors, by this demographic trend.

Key players in the market

Some of the key players in Dipeptide Peptidase 4 Inhibitor market include Merck, Boehringer Ingelheim, Novartis, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Sanofi, Bristol-Myers Squibb and Takeda Pharmaceuticals.

Key Developments:

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. According to a press statement, the acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65 percent of outstanding shares tendered in the takeover offer and regulatory approvals.

In February 2024, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Drug Types Covered:

  • Sitagliptin
  • Vildagliptin
  • Saxagliptin
  • Linagliptin
  • Gemigliptin
  • Anagliptin
  • Teneligliptin
  • Other Drug Types

Applications Covered:

  • Hospitals
  • Clinics
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dipeptide Peptidase 4 Inhibitor Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Sitagliptin
  • 5.3 Vildagliptin
  • 5.4 Saxagliptin
  • 5.5 Linagliptin
  • 5.6 Gemigliptin
  • 5.7 Anagliptin
  • 5.8 Teneligliptin
  • 5.9 Other Drug Types

6 Global Dipeptide Peptidase 4 Inhibitor Market, By Application

  • 6.1 Introduction
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Other Applications

7 Global Dipeptide Peptidase 4 Inhibitor Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Merck
  • 9.2 Boehringer Ingelheim
  • 9.3 Novartis
  • 9.4 AstraZeneca
  • 9.5 GlaxoSmithKline
  • 9.6 Eli Lilly and Company
  • 9.7 Pfizer
  • 9.8 Sanofi
  • 9.9 Bristol-Myers Squibb
  • 9.10 Takeda Pharmaceuticals

List of Tables

  • Table 1 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 4 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 5 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 6 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 7 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 8 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 9 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 10 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 11 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 12 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 13 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 14 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 15 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 17 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 18 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 19 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 20 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 21 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 22 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 23 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 24 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 25 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 26 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 28 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 31 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 32 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 33 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 34 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 35 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 36 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 37 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 38 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 39 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 41 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 42 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 46 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 47 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 48 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 49 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 50 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 51 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 52 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 53 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 54 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 55 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 56 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 57 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 59 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 60 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 61 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 62 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 63 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 64 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 65 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 66 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 67 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 68 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 70 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 71 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 73 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 74 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 75 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 76 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 77 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 78 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 79 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 80 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 81 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 82 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 83 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 84 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)